# Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)

> **NCT00774020** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 9 (actual)

## Conditions studied

- Paget's Disease of Bone

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00774020
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-30
- **Primary completion:** 2011-01-14
- **Final completion:** 2011-01-14
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00774020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00774020, "Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00774020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*